GlassScriptPhysician profile
Elizabeth E Kline
NPI 1639283989
$10,882.02
in general payments reported to CMS, 2019-2025
52 companies · $2,298 in 2025
The $2,298 reported for 2025 was more than what 96% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,298 · 2022: $2,975 · 2023: $1,419 · 2024: $1,892 · 2025: $2,298.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,609.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,608.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $2,687.44 | 2021-2025 | Austedo Xr, Austedo Xr, Austedo |
| Abbott Laboratories | $1,281.56 | 2021-2025 | Proclaim, Eterna, Octrode |
| Abbvie INC. | $666.30 | 2021-2025 | |
| Alexion Pharmaceuticals, INC. | $590.30 | 2021-2025 | Ultomiris, Soliris |
| Ucb, INC. | $535.55 | 2021-2025 | Briviact, Rystiggo, Nayzilam |
| Lundbeck LLC | $463.36 | 2021-2025 | Vyepti |
| Eisai INC. | $362.53 | 2021-2025 | |
| Emd Serono, INC. | $341.16 | 2024-2025 | Mavenclad |
| Amgen INC. | $333.28 | 2021-2025 | Repatha, Uplizna |
| Genzyme Corporation | $308.93 | 2021-2025 | |
| Neurocrine Biosciences, INC. | $286.58 | 2021-2025 | Ingrezza |
| Otsuka America Pharmaceutical, INC. | $194.22 | 2023-2025 | Rexulti, Nuedexta |
| Kyowa Kirin, INC. | $187.38 | 2021-2023 | Nourianz |
| Biohaven Pharmaceutical Holding Company LTD. | $182.06 | 2022 | |
| Biogen, INC. | $161.86 | 2024-2025 | Tysabri, Vumerity, Skyclarys |
Show all 52 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elizabeth Kline listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.